IDEXX Laboratories' CEO Discusses Q4 2012 Results – Earnings Call Transcript

IDEXX Laboratories' CEO Discusses Q4 2012 Results – Earnings Call Transcript
Also in Q4 and for the year, roughly 80% of ProCyte were sold to Catalyst customers with approximately 60% of that subset being to temporaneous purchase of both instruments, evidence of the important role that the dual plays in enabling real-time care … Read more on Seeking Alpha

A Combination Leukemia Can't Take
The dual therapy produced only minor side effects in the study. "If you notice … The trial was conducted at The University of Texas MD Anderson Cancer Center and led by Jan Burger, MD, PhD, associate professor in MD Anderson's Department of Leukemia … Read more on dailyRx

After school shooting, Conn. debates mental health
In written testimony read by her sister on Tuesday, Marquez-Greene suggested that exposing families to trained mental health professionals to de-stigmatize mental health access and treatment. She also called for the state to fully fund programs that … Read more on The Seattle Times